CSIMarket Company Name, Ticker, Competitors, else..
 
Engene Therapeutics Inc   (NASDAQ: ENGN)
 
Price: $1.8550 $0.01 0.815%
Day's High: $1.8698999881744385 Week Perf: -4.87 %
Day's Low: $ 1.80 30 Day Perf: 4.8 %
Volume (M): 657,373 52 Wk High: $ 12.25
Volume (M$): $ 0 52 Wk Avg: $6.02
Open: $1.84 52 Wk Low: $1.40



 Market Capitalization (Millions $) 129
 Shares Outstanding (Millions) 70
 Employees 82
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 51
 Cash Flow (TTM) (Millions $) -33
 Capital Exp. (TTM) (Millions $) 1

Business Description


enGene is a biopharmaceutical company specializing in the development and commercialization of genetic medicines. Their product candidate, detalimogene voraplasmid (formerly EG-70), is intended for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). The company employs the DDX gene delivery platform to develop genetic medicine products targeting mucosal tissues. enGene plans to seek regulatory approval and commercialize its products primarily in the United States.


   Company Address: 4868 Rue Levy, Suite 220 Saint-Laurent 0 QC
   Company Phone Number: 332-4888   Stock Exchange / Ticker: NASDAQ ENGN


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
URGN   -6.41%    
• View Complete Report
   



Business Update

enGene Reports Third Quarter 2025 Financial Results and Provides Business Update

Published Fri, Sep 12 2025 4:14 PM UTC

enGene Holdings Inc. Hits Significant Milestones with Q3 2025 Financials and Strategic AdvancesIn a notable stride towards therapeutic innovation, enGene Holdings Inc. (Nasdaq: ENGN), a clinical-stage, non-viral gene therapy company, has released its financial results for the third quarter ended July 31, 2025. Alongside these results, the company has shared promising busine...
Business Update

enGene Achieves Target Enrollment Milestone for LEGEND Trial Pivotal Cohort

Published Wed, Sep 3 2025 12:27 PM UTC

Breakthrough in Bladder Cancer Treatment: enGene Achieves Key Milestone in Phase 2 LEGEND Trial enGene Holdings Inc. Reaches Target Enrollment in Pivotal Cohort for High-Risk NMIBC Trial BOSTON & MONTREAL enGene Holdings Inc. (Nasdaq: ENGN, enGene or the Company), a pioneering clinical-stage, non-viral gene therapy company, has announced a landmark achievement in its missio...
Business Update

enGene Announces Board and Leadership Appointments to Support Commercial Readiness

Published Tue, Jul 8 2025 3:01 PM UTC

enGene Holdings Inc.: Strategic Leadership Appointments and Financial Progress in Non-Viral Gene-Based Immunotherapy enGene Holdings Inc., a Boston and Montreal-based clinical-stage company specializing in non-viral gene-based immunotherapy, has made significant strides in its strategic positioning, governance, and financial outcomes. This article discusses the recent boar...
Business Update

Engene Holdings Inc Reports Significant Improvement in Leverage Ratio Amid Inducement Grants

Published Fri, Apr 4 2025 1:59 PM UTC

In a recent announcement under NASDAQ Listing Rule 5635(c)(4), Engene Holdings Inc has disclosed a strategic management of its liabilities, leading to notable advancements in its financial health for the first quarter of 2024. The company reported a commendable decrease of 6.74% in repayments of liabilities, contributing to an enhanced leverage ratio of 0.14, which surpasses...
Business Update

enGene Reports Strong Q4 2024 Results and Advances Pivotal Studies in Bladder Cancer Therapy,

Published Fri, Dec 20 2024 8:51 AM UTC

enGene Reports Full Year 2024 Financial Results and Business Update Amid Promising Developments in Cancer Therapy BOSTON & MONTREAL enGene Holdings Inc. (Nasdaq: ENGN), a clinical-stage genetic medicines company known for its innovative non-viral investigational product, detalimogene voraplasmid, has announced its financial results for the full year ending 2024, alongsid...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) 2.65
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 0.51
PEG (TTM) -

Financial Strength Current
Quick Ratio 13.46
Working Capital Ratio 14.06
Leverage Ratio (MRQ) 0.2
Total Debt to Equity 0.1
Interest Coverage (TTM) -
Debt Coverage (TTM) 2.12

Per Share Current
Earnings (TTM) 0.7 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash 3.71 $
Book Value 3.66 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) 623,049
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) 17.93 %
Return On Investment (TTM) 20.05 %
Return On Equity (TTM) 22.58 %
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.